USA – Biogen, a leading biotechnology company renowned for its multiple sclerosis medications, is facing challenges in obtaining clear visibility into Leqembi’s performance and navigating the complexities of its launch in the Alzheimer’s treatment market.  

This comes amid a revelation by the company that it was setting its sight on the lucrative Alzheimer’s disease market.  

With its recently approved drug, Leqembi, Biogen aims to carve out a significant presence in this critical therapeutic area; however, the path ahead for the company is not without obstacles as it lacks precise insight into Leqembi’s market uptake. 

Much of the information about Leqembi’s launch comes from its development partner, Eisai, leading to a somewhat fuzzy understanding of its progress.  

Biogen’s CEO, Chris Viehbacher, acknowledged that there was much uncertainty and revealed that the company was relying on external sources for data. 

The launch of Leqembi has encountered unexpected hurdles, with slower-than-anticipated adoption rates and logistical challenges.  

While initial projections aimed for 10,000 U.S. patients on the drug by March, the actual figures fell short.  

Despite being hailed as a potential blockbuster, Leqembi’s revenue remains modest, reflecting the uphill battle in gaining traction in the market. 

Nevertheless, Biogen remains optimistic about Leqembi’s prospects, citing steady progress and growing demand for the drug.  

To bolster its efforts, the company plans to expand its salesforce and enhance its outreach strategies. With weekly sales showing promising figures, Biogen is doubling down on its commitment to driving Leqembi’s success. 

Also read:

1: Pure Health full year profits declines to US$262M

2: AbbVie completes US$10.1 B ImmunoGen acquisition fortifying oncology pipeline

The journey to accessing Leqembi is complex for patients, requiring multiple steps and confirmatory tests. This intricate process, coupled with the lengthy sales cycle, poses additional challenges for Biogen in achieving widespread adoption of the drug. Despite these hurdles, the company remains steadfast in its pursuit of delivering innovative treatments for Alzheimer’s disease. 

Biogen bets big on Leqembi  

Leqembi’s success is pivotal for Biogen, as it seeks to offset declines in other areas of its business.  

With revenue projections for 2024 showing a potential decline, the company’s focus on new product launches and growth opportunities becomes even more critical. 

 Alongside Leqembi, Biogen is banking on other promising medications to drive its future success, including Qalsody, Zurzuvae, and Skyclarys. 

However, the road ahead is not without its challenges, as evidenced by the discontinuation of Aduhelm, a previous Alzheimer’s drug that faced controversy. 

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.